Jie Dong

4.4k citations
125 papers · 3.0k indexed · h-index 35
Topics
Cancer Immunotherapy and Biomarkers (13 papers)Virus-based gene therapy research (13 papers)CAR-T cell therapy research (12 papers)
Partner nations
ChinaUnited StatesMacao

In The Last Decade

Jie Dong

118 papers receiving 3.0k citations

Peers

Jie Dong
Comparison fields: 5 of 127
  • Molecular Biology 1.1k
  • Oncology 1.0k
  • Immunology 774
  • Cancer Research 523
  • Pulmonary and Respiratory Medicine 454
Replace Latifa Bakiri with:
Latifa Bakiri Austria
Shiyong Li United States
Woo Sung Moon South Korea
Markus J. Mäkinen Finland
Maria Tzardi Greece
Fabio Cianchi Italy
Misa Nakamura Japan
Li‐Wha Wu Taiwan
Yakov Krelin Israel
Jie Dong relative to Latifa Bakiri Austria Latifa Bakiri's profile →
Citations per field
00.5×1.5×
Latifa Bakiri · 1×
Citations per year

Countries citing papers authored by Jie Dong

Since Specialization
Citations

This map shows the geographic impact of Jie Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Dong more than expected).

Fields of papers citing papers by Jie Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jie Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Dong. The network helps show where Jie Dong may publish in the future.

Co-authorship network of co-authors of Jie Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Jie Dong. A scholar is included among the top collaborators of Jie Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jie Dong. Jie Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 0
4 9
5 2
6 0
7 5
8 5
9 7
10 3
11 3
12 24
13 43
14 7
15
Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses
1
16 49
17 4
18 51
19 16
20 18

About Jie Dong

Jie Dong is a scholar working on Oncology, Immunology and Cancer Research, having authored 125 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Virus-based gene therapy research (13 papers) and CAR-T cell therapy research (12 papers). The work is most often cited by research in Oncology (1.0k citations), Immunology (774 citations) and Cancer Research (523 citations). Jie Dong has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Jiwu Wei, Chun Kwok Wong, Shuguang Zuo, Shiqun Wang, Min Wei, Zhe Cai, Delong Jiao, Yi Li, Man Chu and Junhua Wu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026